Bestatin DEVD-FMK Ambrisentan significantly improved exercise capacity

Ambrisentan significantly improved exercise capacity (6-minute walk distance) compared with placebo in two double-blind

and enhanced the anti-tumor efficacy of these agents selectively in p53-deficient tumor cells

follow by the addition of nucleoside triphosphates (NTPs) and [3H]UTP for 3 h at 30°C

InChiKey: ZJVFLBOZORBYFE-UHFFFAOYSA-N

Bestatin DEVD-FMK Ambrisentan significantly improved exercise capacityUbenimex, also known as NK 421 and Bestatin, is a CD13 inhibitor. Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism. Ubenimex synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma. Ubenimex inhibits cell proliferation, migration and invasion by inhibiting the expression of APN and inducing autophagic cell death in prostate cancer